Rituximab in lymphocyte predominance Hodgkin's disease: A case series

Clinical Lymphoma

Volumn 4, Issue 2, 2003, Pages 115-118

  Ibom, Valerie K ^a   Prosnitz, Robert G ^a   Gong, Jerald Z ^a   Moore, Joseph O ^a   DeCastro, Carlos M ^a   Prosnitz, Leonard R ^a   Rizzieri, David A ^a   Gockerman, Jon P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CD20; Chlorambucil; Computed tomography; Immunotherapy; Lymphoma; Monoclonal antibody; Radiation therapy; Toxicity

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MALE; NAUSEA;

EID: 0142217436     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.021     Document Type: Article

References (22)

1. Colby TV, Hoppe RT, Warnke RA. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer 1982; 49:1848-1858.
2. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337:453-458.
3. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-pre-dominant Hodgkin's disease. N Engl J Med 1997; 337:459-465.
4. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease. A distinct clinicopathological entity. Am J Surg Pathol 1994; 18:526-530.
5. Chittal S, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am J Surg Pathol 1988; 12:9-21.
6. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkids disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776-783.
7. Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988; 318:214-219.
8. Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15:3060-3066.
9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
10. von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997; 150:793-803.
11. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
12. Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997; 26:359-368.
13. Crennan E, D'Costa I, Liew KH, et al. Lymphocyte predominant Hodgkin's disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys 1995; 31:333-337.
14. Pappa VI, Norton AJ, Gupta RK, et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 1995; 6:559-565.
15. Jaffe ES, Zarate-Osorno A, Medeiros LJ. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas-lessons learned from composite and sequential malignancies. Semin Diagn Pathol 1992; 9:297-303.
16. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-2195.
17. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
18. Lush RJ, Jones SG, Haynes AP. Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: long-term follow-up of allografting and monoclonal antibody therapy. Br J Haematol 2001; 114:734-735.
19. Rehwald U, Engert A, Diehl V, et al. Monoclonal anti-CD20 antibody rituximab (Rituxan) for treatment of CD20-positive Hodgkin's lymphoma: the German experience. Blood 2000; 96(suppl):729a (Abstract #3153).
20. Ekstrand B, Lucas J, Horwitz S, et al. Rituximab in lymphocyte predominant Hodgkin's disease (LPHD): results of a phase II trial. Proc Am Soc Clin Oncol 2002; 21:264a (Abstract #1052).
21. NCCN practice guidelines for Hodgkin's disease. National Comprehensive Cancer Network. Oncology (Huntingt) 1999; 13:78-110.
22. Carter SK, Livingston RB. Single-agent therapy for Hodgkin's disease. Arch Intern Med 1973; 131:377-387.